The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York A Rare Case of Kidney Failure Due to Diazoxide Toxicity Discussion. PPT FDA Denies Approval of Roxadustat for Anemia in CKD MPR Effects of Dulaglutide in Doxorubicin Induced Renal Toxicity in Rats BTT Dove Medical Press